Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GB5121

Other · developed by GB005, Inc., a wholly owned subsidiary of Gossamer Bio

Phase 1 Most advanced trial (none active)
GOSS Developer
1 Registered trials

What is GB5121?

GB5121 is an investigational drug studied in CNS Lymphoma.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. (GOSS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05242146 Phase 1 CNS Lymphoma Terminated GOSS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CNS Lymphoma

More from GB005, Inc., a wholly owned subsidiary of Gossamer Bio

GB001 Phase 2 GB004 Phase 1 GB1275 Phase 1 Seralutinib Phase 3

Follow GOSS, the company behind GB5121

See GOSS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GOSS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.